Heung Mei Tsui
About Heung Mei Tsui
Heung Mei Tsui is a non‑independent (affiliate) director of China Pharma Holdings, Inc. (CPHI). She has served on CPHI’s board since April 28, 2009 (with prior service from October 2005 to February 2008); her background is as a self‑employed businesswoman engaged in strategic investments and previously in pharmaceutical chemical raw material import/export; she graduated from Hunan Financial & Economic College in 1982 and was disclosed as age 67 in the 2024 proxy .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Self‑employed | Businesswoman engaged in strategic investments | Not disclosed | Brings trading‑side perspective supporting strategic planning and execution |
| Pharmaceutical chemical raw material import/export | Trading/operations | Not disclosed | Commercial trading experience relevant to pharma supply chain |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| None disclosed | — | — | The biography lists other directorships for at least the past five years “if any”; none are shown for Ms. Tsui |
Board Governance
- Independence status: Non‑independent director; identified as an affiliate of the company .
- Committee assignments: Not a member of the Audit Committee (members: G. Michael Bennett–Chair and “audit committee financial expert,” Yingwen Zhang, Baowen Dong; all independent) or the Nominating & Compensation Committee (members: Bennett, Zhang–Chair, Dong; all independent) .
- Meeting cadence and engagement (FY2024): Board held 4 meetings and acted by unanimous written consent 5 times; Audit Committee met 5 times (1 executive session) plus 1 written consent; Nominating & Compensation Committee met 1 time (executive session) and acted by unanimous written consent 2 times; independent directors also held executive sessions at least annually .
Note: The proxy reports meeting counts but does not disclose individual director attendance rates .
- Board leadership: CEO also serves as Chair (combined role) .
Fixed Compensation
Director compensation (Heung Mei Tsui)
| Metric | 2022 | 2024 |
|---|---|---|
| Fees Earned or Paid in Cash ($) | 16,000 | 16,000 |
| Stock Awards ($) | 0 | 0 |
| Option Awards ($) | 0 | 0 |
| Non‑Equity Incentive Plan Compensation ($) | 0 | 0 |
| All Other Compensation ($) | 0 | 0 |
| Total ($) | 16,000 | 16,000 |
Context:
- Independent directors’ engagement letters (Dec 23, 2024): Zhang and Dong—RMB40,000 (~$5,565) each; Bennett—$16,000 plus a warrant to purchase 5,000 shares at $0.19 (no warrants issued as of the proxy). Ms. Tsui (non‑independent) is not covered by these engagement letters .
Performance Compensation
Performance‑linked elements for directors
| Element | 2022 | 2024 | Notes |
|---|---|---|---|
| Stock Awards ($) | 0 | 0 | No equity awards disclosed for Ms. Tsui |
| Option Awards ($) | 0 | 0 | No option grants disclosed for Ms. Tsui |
| Non‑Equity Incentive Plan Compensation ($) | 0 | 0 | No cash incentive plan amounts disclosed |
| Performance Metrics Tied to Director Pay | None disclosed | None disclosed | Director comp tables show no performance‑based elements |
Other Directorships & Interlocks
| Company | Role | Committee Roles | Interlocks/Notes |
|---|---|---|---|
| None disclosed | — | — | Biography lists other directorships if any; none are indicated for Ms. Tsui |
Expertise & Qualifications
- Education: Hunan Financial & Economic College, 1982 .
- Industry/commercial experience: Trading side of pharmaceutical chemical raw materials; brings unique insights into the pharmaceutical industry and benefits the company in strategic planning and execution .
Equity Ownership
| Item | Oct 26, 2023 | Nov 3, 2025 |
|---|---|---|
| Shares Beneficially Owned | 931,266 | 18,626 |
| Percent of Class | 2.9% | <1% |
| Record Date | Oct 26, 2023 | Nov 3, 2025 |
Governance Assessment
-
Positive signals
- Experienced commercial background in pharma trading and strategic investments; board biography cites strategic planning value .
- Oversight committees (Audit; Nominating & Compensation) are composed entirely of independent directors; Audit is chaired by an “audit committee financial expert” (Bennett) .
- Board and committees met regularly in FY2024; independent directors held executive sessions .
- No director/officer legal proceedings disclosed in past ten years .
-
RED FLAGS / Conflicts
- Independence: Ms. Tsui is a non‑independent director and identified as an affiliate of the company .
- Related‑party financing: Ms. Tsui loaned the company $1,354,567 outstanding at Dec 31, 2022 at 1% interest; on Aug 23, 2023 she transferred the debt to CEO Zhilin Li; on Sep 28–29, 2023 the company settled the debt by issuing 13,757,063 shares to Ms. Li—this chain of related‑party transactions is a governance risk .
- Ownership alignment: Latest beneficial ownership shows 18,626 shares (<1%); relatively low “skin in the game” as of Nov 3, 2025 .
- Pay alignment: Director compensation is flat, small, and entirely cash with no equity or performance linkage (e.g., $16,000 in 2022 and 2024), limiting long‑term alignment .
- Board structure: CEO also serves as Chair, which can weaken independent oversight absent a lead independent director .
-
Other observations
- Ms. Tsui does not sit on key oversight committees (Audit; Nominating & Compensation), which preserves committee independence but also limits her direct oversight role .
- Individual attendance rates are not disclosed; only aggregate meeting counts are provided .